Market Overview

The global Anti-Venom Market size was valued at USD 1,240.1 Million in 2024 and is projected to reach USD 2,059.7 Million by 2033. The market is expected to grow at a CAGR of 5.8% during the forecast period 2025-2033. Growth is driven by rising incidences of venomous bites, government initiatives, and biotechnology advancements, particularly in regions with high snakebite cases.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Anti-Venom Market Key Takeaways

• The market size was USD 1,240.1 Million in 2024 and is expected to grow at 5.8% CAGR to USD 2,059.7 Million by 2033.
• North America dominated with over 37.8% market share in 2024.
• Snake species segment holds the largest share at around 52.3% in 2024.
• Polyvalent anti-venom leads the market with 66.7% share due to broad-spectrum effectiveness.
• Neurotoxic mode of action dominates with about 32.3% share in 2024.
• Hospitals are the main end users, holding 62.8% of the market.
• Key players include Pfizer, Bharat Serums and Vaccines, CSL Behring, among others.

Sample Request Link: https://www.imarcgroup.com/anti-venom-market/requestsample

Market Growth Factors

The anti-venom market is primarily driven by the rising incidence of snakebites and venomous insect stings, particularly in tropical and subtropical regions. According to WHO, between 4.5 and 5.4 million snakebite incidents occur annually, resulting in 81,000 to 138,000 deaths and 1.8 to 2.7 million cases of clinical disease. Factors such as rapid urbanization, deforestation, and climate change have increased human encounters with venomous species, escalating demand for effective treatments to reduce fatalities and complications.

Advancements in biotechnology significantly enhance anti-venom development. The emergence of monoclonal antibody-based anti-venoms offers faster, safer, and more targeted therapies. New research into venom immunotherapy and recombinant technologies broadens available treatment options, lowers production costs, and improves accessibility. For example, in July 2024, research discovered heparin as an affordable counteragent for cobra venom, potentially lowering treatment costs globally.

Government and healthcare support play a crucial role, with increased funding and initiatives to ensure anti-venom availability in rural and underserved areas. Collaborative efforts between public health organizations and NGOs help raise awareness and improve emergency responses. For instance, India's National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) launched in March 2024 aims to halve snakebite deaths by 2030 through integrated health actions across human, animal, and environmental health sectors.

Market Segmentation

Analysis by Species:

• Snake: Largest segment with 52.3% share in 2024 due to high global snakebite incidence, especially in tropical/subtropical regions. Treatment demand arises from morbidity and mortality risks and venom diversity requiring specialized anti-venoms.
• Scorpion
• Spider
• Others

Analysis by Anti-venom Type:

• Polyvalent Anti-venom: Leading segment with 66.7% share in 2024 due to broad-spectrum efficacy against multiple venomous species, valuable for diverse regions and emergency cases.
• Monovalent Anti-venom

Analysis by Mode of Action:

• Neurotoxic: Dominates with 32.3% share in 2024, driven by the severity and prevalence of neurotoxic envenomation from species like cobras and kraits, requiring immediate treatment.
• Cytotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

Analysis by End User:

• Hospitals: Account for the largest share at 62.8% in 2024, as they provide emergency care and monitoring with specialized facilities for venomous bites.
• Clinics
• Ambulatory Surgical Centers

Regional Insights

North America is the dominant region in the anti-venom market, accounting for over 37.8% market share in 2024. The growth is supported by a high prevalence of venomous species like rattlesnakes and black widows, advanced healthcare infrastructure, government initiatives, and public awareness. Technological advances and research in monoclonal antibody-based treatments also bolster the region's market leadership.

Recent Developments & News

• August 2024: Three companies including Echitab Study Limited and Nigeria's Federal Ministry of Health signed an MoU for local anti-snake venom production to alleviate national shortages.
• August 2024: MicroPharm UK partnered with Nigeria's AMA Medical Manufacturing for affordable anti-venom production with a multi-million-dollar investment and technology transfer.
• August 2022: Bharat Serums and Vaccines Ltd. collaborated with the Indian Institute of Science to develop more effective snakebite antivenoms.
• March 2022: Ophirex, Inc. received U.S. FDA Fast Track for an oral broad-spectrum anti-venom treatment, varespladib-methyl, targeting U.S. and India markets.
• April 2021: Rare Disease Therapeutics, Inc. expanded FDA approval for ANAVIP antivenom to cover all North American Pit Vipers, enhancing treatment options.

Key Players

• Bharat Serums and Vaccines Limited (BSV)
• Boehringer Ingelheim International GmbH
• Boston Scientific Corporation
• CSL Limited
• Haffkine Bio-Pharmaceutical Corporation Limited
• Incepta Pharmaceuticals Limited
• Merck & Co. Inc.
• Merck KGaA
• MicroPharm Limited
• Pfizer Inc.
• Rare Disease Therapeutics Inc.

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=5147&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302